tiprankstipranks
Advertisement
Advertisement

BMRN Stock Latest News

BioMarin Acquisition of Alesta Therapeutics Reinforces Growth Strategy; Whitney Ijem Reiterates Buy Rating and Maintains $114 Price Target
RatingsBioMarin Acquisition of Alesta Therapeutics Reinforces Growth Strategy; Whitney Ijem Reiterates Buy Rating and Maintains $114 Price Target
22h ago
BMRN
BMO starts BioMarin at Outperform, sees slower fade for Voxzogo
PremiumThe Fly
BMO starts BioMarin at Outperform, sees slower fade for Voxzogo
1d ago
BMRN
BioMarin initiated with an Outperform at BMO Capital
PremiumThe Fly
BioMarin initiated with an Outperform at BMO Capital
2d ago
BMRN
BioMarin price target lowered to $59 from $60 at H.C. Wainwright
PremiumThe Fly
BioMarin price target lowered to $59 from $60 at H.C. Wainwright
2d ago
BMRN
BioMarin to Acquire Alesta Therapeutics, Expanding Skeletal Pipeline
PremiumCompany Announcements
BioMarin to Acquire Alesta Therapeutics, Expanding Skeletal Pipeline
2d ago
8K
BMRN
BioMarin to acquire Alesta Therapeutics for $275M plus payments
PremiumThe FlyBioMarin to acquire Alesta Therapeutics for $275M plus payments
2d ago
BMRN
BioMarin price target raised to $88 from $82 at Piper Sandler
Premium
The Fly
BioMarin price target raised to $88 from $82 at Piper Sandler
3d ago
BMRN
BioMarin price target raised to $111 from $105 at Barclays
Premium
The Fly
BioMarin price target raised to $111 from $105 at Barclays
3d ago
BMRN
BioMarin price target raised to $114 from $111 at Canaccord
PremiumThe Fly
BioMarin price target raised to $114 from $111 at Canaccord
10d ago
BMRN
BioMarin price target raised to $80 from $75 at Wells Fargo
PremiumThe Fly
BioMarin price target raised to $80 from $75 at Wells Fargo
10d ago
BMRN
BioMarin price target raised to $86 from $80 at BofA
PremiumThe Fly
BioMarin price target raised to $86 from $80 at BofA
13d ago
BMRN
BioMarin price target raised to $124 from $119 at Morgan Stanley
PremiumThe Fly
BioMarin price target raised to $124 from $119 at Morgan Stanley
13d ago
BMRN
BioMarin price target raised to $105 from $100 at Raymond James
PremiumThe FlyBioMarin price target raised to $105 from $100 at Raymond James
13d ago
BMRN
BioMarin Buy Rating Reaffirmed as Strong Voxzogo Performance and Pipeline Progress Support Durable Growth; $94 Price Target Maintained
Premium
Ratings
BioMarin Buy Rating Reaffirmed as Strong Voxzogo Performance and Pipeline Progress Support Durable Growth; $94 Price Target Maintained
13d ago
BMRN
BioMarin price target raised to $70 from $68 at Stifel
Premium
The Fly
BioMarin price target raised to $70 from $68 at Stifel
13d ago
BMRN
BioMarin price target raised to $97 from $95 at Oppenheimer
PremiumThe Fly
BioMarin price target raised to $97 from $95 at Oppenheimer
13d ago
BMRN
BioMarin price target raised to $60 from $50 at H.C. Wainwright
PremiumThe Fly
BioMarin price target raised to $60 from $50 at H.C. Wainwright
13d ago
BMRN
BioMarin reports Q2 non-GAAP EPS $1.20, consensus 95c
PremiumThe Fly
BioMarin reports Q2 non-GAAP EPS $1.20, consensus 95c
14d ago
BMRN
BioMarin raises 2026 non-GAAP EPS view to $4.90-$5.10 from $4.85-$5.05
PremiumThe Fly
BioMarin raises 2026 non-GAAP EPS view to $4.90-$5.10 from $4.85-$5.05
14d ago
BMRN
Is BMRN a Buy, Before Earnings?
PremiumPre-EarningsIs BMRN a Buy, Before Earnings?
16d ago
BMRN
Spruce Biosciences appoints Jessica Cohen Pfeffer as VP, clinical development
Premium
The Fly
Spruce Biosciences appoints Jessica Cohen Pfeffer as VP, clinical development
17d ago
BMRN
SPRB
BioMarin and n-Lorem Foundation enter research collaboration in ReNU syndrome
Premium
The Fly
BioMarin and n-Lorem Foundation enter research collaboration in ReNU syndrome
24d ago
BMRN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >